-
随着一体化PET/MRI的发展,PET/MRI心肌显像受到越来越多的关注[1]。赵军和刘中民[2]综述了PET/MRI一体机在心血管疾病中的应用进展,认为PET与MRI互补可以精确地判断存活心肌和心脏功能,准确评估心脏冠状动脉硬化的程度和心肌纤维化程度,但目前PET/MRI在心血管疾病中的研究较少,亟需大样本前瞻性单中心或多中心研究。覃春霞等[3]对一体化PET/MRI在心脏显像中的技术问题及其在缺血性心脏病中的临床应用现状及前景进行了综述,认为近年来一些小样本研究结果展现了PET/MRI在缺血性心脏病中的初步应用价值,但未能充分利用其可同时采集的优势,衰减校正方法和运动校正方法等仍需进一步改进。我们从18F-FDG PET/MRI存活心肌显像的摄取机制着手,分析PET和MRI信息的互补性,结合近10年来的研究进展,对18F-FDG PET/MRI存活心肌显像的临床价值进行综述。
18F-FDG PET/MRI在存活心肌诊断中的研究进展
Application Progress of 18F-FDG PET/MRI in the diagnosis of viable myocardium
-
摘要: 18F-氟脱氧葡萄糖(FDG)PET/MRI存活心肌显像一直受到临床特别是心内科医师的关注,PET和MRI均可在缺血性心肌病的诊断和预后评估中发挥独特价值,一体化PET/MRI设备为探索其整合价值提供了新平台。笔者通过回顾缺血性心肌病的病理生理学、PET心肌显像的特点和MRI的临床应用情况,梳理近10年来相关领域的研究进展,对PET/MRI存活心肌显像的特点及其临床价值进行综述,为PET/MRI存活心肌显像临床科研工作的开展提供参考。
-
关键词:
- 正电子发射断层显像术 /
- 磁共振成像 /
- 氟脱氧葡萄糖F18 /
- 心肌
Abstract: 18F-fluorodeoxyglucose (FDG) PET/MRI imaging of viable myocardium has always been concerned by clinicians, especially cardiologists. Both PET and MRI can play a unique value in the diagnosis and prognosis of ischemic cardiomyopathy. Integrated PET/MRI equipment provides a new platform for exploring its integrated value. By reviewing the pathophysiology of ischemic cardiomyopathy, the characteristics of PET myocardial imaging and the clinical application of MRI, and combing the research progress in related fields in the past ten years, the author reviews the characteristics and clinical value of PET/MRI viable myocardial imaging, so as to provide reference for the clinical scientific research of PET/MRI viable myocardial imaging. -
[1] Broski SM, Goenka AH, Kemp BJ, et al. Clinical PET/MRI: 2018 update[J]. AJR Am J Roentgenol, 2018, 211(2): 295−313. DOI: 10.2214/AJR.18.20001. [2] 赵军, 刘中民. PET/MR一体机在心血管疾病中的应用进展[J]. 中华核医学与分子影像杂志, 2020, 40(8): 494−500. DOI: 10.3760/cma.j.cn321828-20200218-00049.
Zhao J, Liu ZM. Application advances of simultaneous PET/MR imaging in cardiovascular disease[J]. Chin J Nucl Med Mol Imaging, 2020, 40(8): 494−500. DOI: 10.3760/cma.j.cn321828-20200218-00049.[3] 覃春霞, 张永学, 汪朝晖, 等. 一体化PET/MR用于缺血性心脏病进展[J]. 中国医学影像技术, 2021, 37(5): 768−771. DOI: 10.13929/j.issn.1003-3289.2021.05.034.
Qin CX, Zhang YX, Wang ZH, et al. Application progress of hybrid PET/MR in ischemic heart diseases[J]. Chin J Med Imaging Technol, 2021, 37(5): 768−771. DOI: 10.13929/j.issn.1003-3289.2021.05.034.[4] Wijns W, Vatner SF, Camici PG. Hibernating myocardium[J]. N Engl J Med, 1998, 339(3): 173−181. DOI: 10.1056/nejm199807163390307. [5] Sarikaya I, Elgazzar AH, Alfeeli MA, et al. Status of F-18 fluorodeoxyglucose uptake in normal and hibernating myocardium after glucose and insulin loading[J]. J Saudi Heart Assoc, 2018, 30(2): 75−85. DOI: 10.1016/j.jsha.2017.07.001. [6] Manabe O, Oyama-Manabe N, Naya M, et al. Pitfalls of 18F-FDG PET for evaluating myocardial viability[J]. J Nucl Cardiol, 2017, 24(3): 1110−1113. DOI: 10.1007/s12350-016-0572-6. [7] Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications[J]. Eur J Nucl Med Mol Imaging, 2009, 36(Suppl 1): S121−130. DOI: 10.1007/s00259-008-0980-1. [8] 李坤成, 张振. 心脏MR特征追踪技术进展及其临床应用[J]. 中国医学影像技术, 2022, 38(1): 1−5. DOI: 10.13929/j.issn.1003-3289.2022.01.001.
Li KC, Zhang Z. Progresses of cardiac MR feature tracking technology and clinical applications[J]. Chin J Med Imaging Technol, 2022, 38(1): 1−5. DOI: 10.13929/j.issn.1003-3289.2022.01.001.[9] Libby P, Bonow R, Zipes D, et al. Braunwald's heart disease: a textbook of cardiovascular medicine[M]. 8th ed. Philadelphia: Saunders, 2007. [10] Soares ROS, Losada DM, Jordani MC, et al. Ischemia/reperfusion injury revisited: an overview of the latest pharmacological strategies[J/OL]. Int J Mol Sci, 2019, 20(20): 5034[2023-02-11]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834141. DOI: 10.3390/ijms20205034. [11] Kloner RA. Stunned and hibernating myocardium: where are we nearly 4 decades later?[J/OL]. J Am Heart Assoc, 2020, 9(3): e015502[2023-02-11]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033879. DOI: 10.1161/JAHA.119.015502. [12] Buffa V, Di Renzi P. CMR in the diagnosis of ischemic heart disease[J]. Radiol Med, 2020, 125(11): 1114−1123. DOI: 10.1007/s11547-020-01278-9. [13] Kim RJ, Shah DJ. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough[J]. Heart, 2004, 90(2): 137−140. DOI: 10.1136/hrt.2003.023101. [14] Kim RJ, Albert TSE, Wible JH, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial[J]. Circulation, 2008, 117(5): 629−637. DOI: 10.1161/CIRCULATIONAHA.107.723262. [15] Hope TA, Fayad ZA, Fowler KJ, et al. Summary of the first ISMRM-SNMMI workshop on PET/MRI: applications and limitations[J]. J Nucl Med, 2019, 60(10): 1340−1346. DOI: 10.2967/jnumed.119.227231. [16] Munoz C, Kunze KP, Neji R, et al. Motion-corrected whole-heart PET-MR for the simultaneous visualisation of coronary artery integrity and myocardial viability: an initial clinical validation[J]. Eur J Nucl Med Mol Imaging, 2018, 45(11): 1975−1986. DOI: 10.1007/s00259-018-4047-7. [17] Lassen ML, Rasul S, Beitzke D, et al. Assessment of attenuation correction for myocardial PET imaging using combined PET/MRI[J]. J Nucl Cardiol, 2019, 26(4): 1107−1118. DOI: 10.1007/s12350-017-1118-2. [18] Munoz C, Ellis S, Nekolla SG, et al. MR-guided motion-corrected PET image reconstruction for cardiac PET-MR[J]. J Nucl Med, 2021, 62(12): 1768−1774. DOI: 10.2967/jnumed.120.254235. [19] Zhang Z, Chen X, Wan Q, et al. A two-stage cardiac PET and late gadolinium enhancement MRI co-registration method for improved assessment of non-ischemic cardiomyopathies using integrated PET/MR[J]. Eur J Nucl Med Mol Imaging, 2022, 49(7): 2199−2208. DOI: 10.1007/s00259-022-05681-4. [20] Von Felten E, Benetos G, Patriki D, et al. Myocardial creep-induced misalignment artifacts in PET/MR myocardial perfusion imaging[J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 406−413. DOI: 10.1007/s00259-020-04956-y. [21] Carballo D, Nkoulou R, Vincenti G, et al. Value of a hybrid PET/MRI in the assessment of cardiac viability[J]. J Cardiovasc Magn Reson, 2012, 14(Suppl 1): SP80. DOI: 10.1186/1532-429X-14-S1-P80. [22] Nensa F, Poeppel TD, Beiderwellen K, et al. Hybrid PET/MR imaging of the heart: feasibility and initial results[J]. Radiology, 2013, 268(2): 366−373. DOI: 10.1148/radiol.13130231. [23] Beitzke D, Rasul S, Lassen ML, et al. Assessment of myocardial viability in ischemic heart disease by PET/MRI: comparison of left ventricular perfusion, hibernation, and scar burden[J]. Acad Radiol, 2020, 27(2): 188−197. DOI: 10.1016/j.acra.2019.03.021. [24] Barrio P, López-Melgar B, Fidalgo A, et al. Additional value of hybrid PET/MR imaging versus MR or PET performed separately to assess cardiovascular disease[J/OL]. Rev Esp Cardiol (Engl Ed), 2021, 74(4): 303−311[2023-02-11]. https://www.sciencedirect.com/science/article/abs/pii/S188558572030373X. DOI: 10.1016/j.rec.2020.06.034. [25] Priamo J, Adamopoulos D, Rager O, et al. Downstream indication to revascularization following hybrid cardiac PET/MRI: preliminary results[J]. Nucl Med Commun, 2017, 38(6): 515−522. DOI: 10.1097/MNM.0000000000000680. [26] Wech T, Kunze KP, Rischpler C, et al. A compressed sensing accelerated radial MS-CAIPIRINHA technique for extended anatomical coverage in myocardial perfusion studies on PET/MR systems[J]. Phys Med, 2019, 64: 157−165. DOI: 10.1016/j.ejmp.2019.06.010. [27] Nensa F, Poeppel T, Tezgah E, et al. Integrated FDG PET/MR imaging for the assessment of myocardial salvage in reperfused acute myocardial infarction[J]. Radiology, 2015, 276(2): 400−407. DOI: 10.1148/radiol.2015140564. [28] Bulluck H, White SK, Fröhlich GM, et al. Quantifying the area at risk in reperfused ST-segment-elevation myocardial infarction patients using hybrid cardiac positron emission tomography-magnetic resonance imaging[J]. Circ Cardiovasc Imaging, 2016, 9(3): e003900. DOI: 10.1161/circimaging.115.003900. [29] Rischpler C, Langwieser N, Souvatzoglou M, et al. PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(6): 661−669. DOI: 10.1093/ehjci/jeu317. [30] Vitadello T, Kunze KP, Nekolla SG, et al. Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions[J]. Eur J Nucl Med Mol Imaging, 2020, 47(13): 3074−3083. DOI: 10.1007/s00259-020-04877-w.
计量
- 文章访问数: 3020
- HTML全文浏览量: 2476
- PDF下载量: 39